GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
NCT ID: NCT05085639
Last Updated: 2021-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2021-11-30
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLS-5310 1.2 mg (Group 1)
GLS-5310 1.2 mg (ID + Gene-Derm) at Day 0 and Week 8
GLS-5130
GLS-5310 DNA plasmid vaccine
GLS-5310 2.4 mg (Group 2)
GLS-5310 1.2 mg (ID + Gene-Derm) + 1.2 mg (IN) at Day 0 and Week 8
GLS-5130
GLS-5310 DNA plasmid vaccine
GLS-5310 1.2 mg (Group 3)
GLS-5310 1.2 mg ID at Day 0 and Week 8
GLS-5130
GLS-5310 DNA plasmid vaccine
Placebo (Group 4)
Placebo (ID + Gene-Derm) at Day 0 and Week 8
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLS-5130
GLS-5310 DNA plasmid vaccine
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able to provide informed consent
3. Able and willing to comply with study procedures
4. For women of childbearing potential, able and willing to use an approved form of pregnancy prevention during the study
5. Negative test result for the presence of SARS-CoV-2 IgM and IgG antibodies, which indicate recent or prior infection
Exclusion Criteria
2. Persons with symptoms in the past 2 weeks consistent with possible acute SARS-CoV-2 infection to include fever, loss of smell or taste
3. Persons diagnosis of type 2 diabetes mellitus
4. Persons with a diagnosis of chronic kidney disease
5. Persons with a diagnosis of chronic obstructive pulmonary disease (COPD)
6. Persons with a diagnosis of heart conditions to include heart failure, coronary artery disease, prior heart attack, cardiomyopathy
7. Obesity (BMI of 30 kg/m2 or greater)
8. Sickle cell disease
9. Current or former smoker
10. Current or planned pregnancy during the study
11. Currently breastfeeding
12. Current or past participation in a coronavirus (MERS-CoV, SARS-CoV-2) vaccine study, or receipt of a SARS-CoV-2 vaccine that has been approved by the FDA, including vaccines that have received Emergency Use Authorization (EUA)
13. Administration of an investigational agent within 90 days of the 1st dose
14. Administration of a vaccine within 2 weeks prior to the 1st dose
15. Administration of immune globulin within 6 months of enrollment
16. Administration of an anti-TNFα inhibitor such as infliximab, adalimumab, etanercept, or anti-CD20 monoclonal antibody rituximab within 6 months from enrollment
17. Current daily treatment of systemic corticosteroids of 20 mg of prednisone or greater; or the equivalent dose of other systemic corticosteroids
18. Treatment within the four weeks prior to enrollment with any drug intended for the prophylaxis or treatment of COVID-19
19. Any prior treatment with an anti-SARS-CoV-2 monoclonal antibody or immune serum
20. Prior treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal antibody, or anti-JAK inhibitor (see Appendix B exclusionary period for specific drugs)
21. History of malignancy
22. History of transplantation (any organ or bone marrow)
23. Current or planned chemotherapy treatment for hematologic or solid tumor during study period
24. History of other congenital or acquired immunodeficiency, excluding those with HIV infection who are taking highly active antiretroviral therapy and who have documentation of undetectable serum viral load
25. History of PCR-confirmed infection with SARS-CoV-2
26. Not willing to allow storage and future use of samples for SARS-CoV-2 related research and who have a CD4 count \> 200 cells/µL on two measures at least 3 months apart
27. Prisoner or subjects who are compulsorily detained for treatment of a psychiatric illness
28. Any illness or condition that, in the opinion of the investigator, may affect the safety of the subject or the evaluation of a study endpoint
29. History of chronic rhinosinusitis
30. History of nasal septal defect or deviated nasal septum
31. History of cleft palate
32. History of nasal polyps
33. History of other disorders that, in the opinion of the investigator, may adversely affect administration of intranasal vaccine
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GeneOne Life Science, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Puerto Rico
San Juan, PR, Puerto Rico
University of Puerto Rico
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ileana Boneta
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CoV2-002
Identifier Type: -
Identifier Source: org_study_id